87 related articles for article (PubMed ID: 3488924)
21. Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas.
Baldwin RW; Pimm MV
Rev Eur Etud Clin Biol; 1971 Nov; 16(9):875-81. PubMed ID: 4945964
[No Abstract] [Full Text] [Related]
22. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
[TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy of malignant tumors with subpopulations of T lymphocytes].
Fernández-Cruz E
Rev Esp Oncol; 1982; 29(4):701-10. PubMed ID: 6242320
[TBL] [Abstract][Full Text] [Related]
25. [Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2].
Mir LM; Roth C; Orlowski S; Belehradek J; Fradelizi D; Paoletti C; Kourilsky P
C R Acad Sci III; 1992; 314(12):539-44. PubMed ID: 1381659
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
Kedar E; Chriqui-Zeira E; Kyriazis AP
J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
[TBL] [Abstract][Full Text] [Related]
27. Association of minisatellite instability with c-myc amplification and K-ras mutation in methylcholanthrene-induced mouse sarcomas.
Niwa O; Kamiya K; Furihata C; Nitta Y; Wang Z; Fan YJ; Ninomiya Y; Kotomura N; Numoto M; Kominami R
Cancer Res; 1995 Dec; 55(23):5670-6. PubMed ID: 7585652
[TBL] [Abstract][Full Text] [Related]
28. Tumour inhibitory effects of TCGF/IL-2/-containing preparations.
Bubeník J; Indrová M; Perlmann P; Berzins K; Mach O; Kraml J; Toulcová A
Cancer Immunol Immunother; 1985; 19(1):57-61. PubMed ID: 3872165
[TBL] [Abstract][Full Text] [Related]
29. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.
Forni G; Giovarelli M; Santoni A
J Immunol; 1985 Feb; 134(2):1305-11. PubMed ID: 3871210
[TBL] [Abstract][Full Text] [Related]
30. Effect of modified tumor antigen on experimentally induced sarcomas.
Nigam SK; Bhatt VH
Saudi Med J; 2001 Feb; 22(2):157-63. PubMed ID: 11299413
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis.
Suga T; Shiio T; Maeda YY; Chihara G
Cancer Res; 1984 Nov; 44(11):5132-7. PubMed ID: 6488173
[TBL] [Abstract][Full Text] [Related]
32. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
33. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
[TBL] [Abstract][Full Text] [Related]
34. Effect of prophylactic and therapeutic administration of BCG vaccine on growth of experimental sarcoma.
Símová J; Bubeník J
Folia Biol (Praha); 1975; 21(5):329-33. PubMed ID: 172377
[TBL] [Abstract][Full Text] [Related]
35. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
[TBL] [Abstract][Full Text] [Related]
36. Cancare-a herbal formulation inhibits chemically induced tumours in experimental animals.
Rajeshkumar NV; Kuttan R
Indian J Exp Biol; 2001 Jul; 39(7):654-9. PubMed ID: 12019758
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T cell subset and nature of suppression.
Fernandez-Cruz E; Gilman SC; Feldman JD
J Immunol; 1982 Mar; 128(3):1112-7. PubMed ID: 6460058
[TBL] [Abstract][Full Text] [Related]
38. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
39. Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas.
Spence RJ; Simon RM; Baker AR
J Natl Cancer Inst; 1978 Feb; 60(2):451-9. PubMed ID: 621758
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of tumor-bearing mice with chemically modified tumor membrane fractions of two syngeneic tumor cell lines.
Staab HJ; Anderer FA
Cancer Detect Prev; 1984; 7(4):279-88. PubMed ID: 6091881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
